Increlex
Drug
Ipsen Pharma SAS
Total Payments
$242,547
Transactions
566
Doctors
238
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $13,571 | 8 | 1 |
| 2023 | $155,019 | 32 | 8 |
| 2018 | $23,427 | 275 | 179 |
| 2017 | $50,530 | 251 | 107 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $191,609 | 34 | 79.0% |
| Consulting Fee | $19,450 | 9 | 8.0% |
| Food and Beverage | $14,494 | 497 | 6.0% |
| Space rental or facility fees (teaching hospital only) | $11,500 | 5 | 4.7% |
| Travel and Lodging | $5,448 | 20 | 2.2% |
| Education | $46.00 | 1 | 0.0% |
Payments by Type
Research
$191,609
34 transactions
General
$50,938
532 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD). | Ipsen Pharma SAS | $155,444 | 0 |
| Treatment With Recombinant Human Insulin-like Growth Factor 1 rhIGF-1 in Patients WithPappalysin-2PAPP-A2 Gene Mutation | Ipsen Biopharmaceuticals, Inc | $13,220 | 0 |
| Treatment with recombinant human insulin-like growth factor 1 (rhIGF-1) in patients with pappalysin-2 (PAPP-A2) gene mutation | Ipsen Biopharmaceuticals, Inc | $12,945 | 0 |
| IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency | Ipsen Biopharmaceuticals, Inc | $10,000 | 0 |
Top Doctors Receiving Payments for Increlex — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Pediatrics | Elmhurst, NY | $68.78 | 3 |
| , M.D | Pediatric Endocrinology | Bronx, NY | $65.98 | 4 |
| , MD | Pediatrics | Phoenix, AZ | $64.97 | 3 |
| , MD | Pediatric Endocrinology | Miami, FL | $63.27 | 3 |
| , MD | Pediatric Endocrinology | Los Angeles, CA | $63.11 | 2 |
| , MD | Internal Medicine | Odessa, TX | $62.34 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Staten Island, NY | $62.34 | 1 |
| James Burks | — | Odessa, TX | $62.34 | 1 |
| , MD | Pediatric Endocrinology | Long Beach, CA | $62.09 | 3 |
| , D.O | Pediatric Endocrinology | Shrewsbury, NJ | $59.85 | 3 |
| , M.D | Pediatric Endocrinology | Orange, CA | $55.49 | 2 |
| , MD | Pediatric Endocrinology | Orange, CA | $55.49 | 2 |
| , M.D | Dermatology | Oxnard, CA | $54.83 | 2 |
| , M.D | Pediatric Hematology-Oncology | Ventura, CA | $54.83 | 2 |
| , MD | Endocrinology, Diabetes & Metabolism | Norman, OK | $51.53 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Norman, OK | $51.53 | 1 |
| , DO | Pediatric Endocrinology | Phoenix, AZ | $50.46 | 2 |
| , MD | Pediatric Endocrinology | Chattanooga, TN | $46.60 | 2 |
| , MD | Pediatrics | Detroit, MI | $46.38 | 3 |
| , MD | Pediatric Endocrinology | Miami, FL | $46.00 | 1 |
| , M.D | Pediatrics | Bronx, NY | $43.11 | 3 |
| , MD | Pediatric Endocrinology | Nashville, TN | $42.66 | 2 |
| , MD | Pediatric Hematology-Oncology | Nashville, TN | $42.66 | 2 |
| , MD | Pediatric Endocrinology | Nashville, TN | $42.66 | 2 |
| , M.D | Pediatrics | Phoenix, AZ | $41.91 | 2 |
Ad
Manufacturing Companies
- Ipsen Pharma SAS $155,444
- Ipsen Biopharmaceuticals, Inc $87,103
Product Information
- Type Drug
- Total Payments $242,547
- Total Doctors 238
- Transactions 566
About Increlex
Increlex is a drug associated with $242,547 in payments to 238 healthcare providers, recorded across 566 transactions in the CMS Open Payments database. The primary manufacturer is Ipsen Pharma SAS.
Payment data is available from 2017 to 2024. In 2024, $13,571 was paid across 8 transactions to 1 doctors.
The most common payment nature for Increlex is "Unspecified" ($191,609, 79.0% of total).
Increlex is associated with 4 research studies, including "Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD)." ($155,444).